KOOL: news (interesting niche these guys have)
Might be something to keep an eye on, low float....
(COMTEX) B: THERMOGENESIS CORP. Places Fourth BioArchive System in Ja
B: THERMOGENESIS CORP. Places Fourth BioArchive System in Japan
RANCHO CORDOVA, Calif., Jul 12, 2000 (BUSINESS WIRE) --
Hyogo Cord Blood Bank, Kobe City becomes the fourth placental cord
blood (PCB) bank in Japan to adopt the BioArchive(R) System
THERMOGENESIS CORP. (Nasdaq:KOOL) announced the sale of a BioArchive System to
the Hyogo Cord Blood Bank in Kobe City, Japan. BioArchive Systems are also used
by the major Cord Blood Banks in Belgium, China, Taiwan, Germany, Mexico, Spain,
Finland, United Kingdom and in the U.S. pursuant to IND regulations.
Phil Coelho, CEO of THERMOGENESIS CORP. noted that "...This will be the fourth
BioArchive System chosen by a PCB bank in Japan, joining identical systems at
the University of Tokyo Medical Center, Hokkaido Red Cross Blood Center and
Nihon University Medical Center. The BioArchive System is demonstrably the
international standard for collecting, processing, and archiving cryopreserved
hematopoietic stem cells sourced from placental/cord blood (PCB)." PCB stem
cells are used to reconstitute the hematopoietic and immune systems of patients
who have undergone high-dose chemotherapy and radiation to combat diseases such
as leukemias, lymphomas, diverse inherited anemias such as sickle cell anemia
and thalassemia and other genetic diseases.
The Hyogo Cord Blood Bank plans to store 400 PCB stem cell units in the first
year and build to 20,000 units in later years. Dr. James Godsey, President and
COO of THERMOGENESIS CORP. commented, "We are pleased that the Hyogo Cord Blood
Bank has chosen the BioArchive System for their cord blood banking program and
are joining the ever growing number of public cord blood banking programs around
the world who have adopted this system as their standard. Japanese PCB banks
have already provided PCB units for 207 transplants and this source of
hematopoietic stem cells is rapidly replacing bone marrow in Japan."
The BioArchive System uses THERMOGENESIS CORP.'s proprietary computer-driven
liquid nitrogen robotic system to cryopreserve and archive up to 3,626 units
that have been collected and preserved in proprietary sterile plastic bag sets.
The BioArchive System tracks identification and location for each unit and
performs robotic retrieval of each unique tissue-typed unit for use in
life-saving transplantation. The BioArchive System operates to freeze, place and
retrieve samples without exposing other archived samples to detrimental
temperature changes. In the U.S., the THERMOGENESIS CORP. BioArchive System is a
Class II exempt device intended for the preservation of blood components and
blood products.
The BioArchive System has additional potential applications involving archiving,
storing, managing and retrieving other kinds of biological specimens, including
peripheral blood-derived stem-cells, cell lines, male sperm cells, female eggs,
heart valves, corneas, virus samples, biopsy samples and other blood, tissue and
saliva samples. Use of the BioArchive System in the above applications may be
subject to certain regulations.
About Hyogo Cord Blood Bank
The Hyogo Cord Blood Bank is located in Kobe City, Japan, 370 miles southwest of
Tokyo, and is a non-profit organization under the leadership of Director
General, Mr. Osaji Asio, Chairman of the Minato Bank Ltd. in Kobe and the
Medical Director, Hiroshi Hara, MD, an internationally celebrated
immunogeneticist. The Hyogo Cord Blood Bank's basic operating funds will be
largely dependent on government support and donations by individuals and
corporations.
About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and
distributing equipment to collect, cryopreserve and archive highly sensitive
blood products and biological tissue for more than 10 years.
The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the company's control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the Company's filings with the Securities and Exchange
Commission. |
